VKTX Latest Headlines

Viking Therapeutics Lines Up Five Investor Conferences as VK2735 Advances in Phase 3 Obesity Studies

Market Chameleon (Wed, 4-Nov 8:00 AM)

Viking’s VK2735 Obesity Program Adds Oral Phase 3 While $960 Million Cash Pile Fuels Multi-Trial Push

Market Chameleon (Thu, 29-Oct 7:59 AM)

Viking Therapeutics sets Oct. 28 earnings date with Phase 3 obesity program VK2735 in focus

Market Chameleon (Thu, 22-Oct 8:29 AM)

Viking Therapeutics Begins Part 2 Maintenance Study Testing Oral VK2735 After 21 Weeks of Weekly Injections

Market Chameleon (Tue, 6-Oct 7:33 AM)

Viking Therapeutics closes $575 million financing to fund Phase 3 obesity program VK2735 and broader pipeline

Market Chameleon (Tue, 29-Sep 7:42 AM)

Viking Therapeutics Plans $200 Million Stock Deal and $200 Million Convertible Notes to Fund VK2735 and VK3019

Market Chameleon (Thu, 24-Sep 11:39 AM)

Viking Therapeutics maps out $400 million financing plan to advance VK2735 and VK3019

Market Chameleon (Thu, 24-Sep 7:06 AM)

VKTX rallies after VK2735 maintenance study shows up to 97% of weight loss preserved on every-other-week dosing

Market Chameleon (Tue, 22-Sep 10:28 AM)

Viking’s VK2735 maintenance study highlights up to 97% weight-loss retention on every-other-week dosing

Market Chameleon (Tue, 22-Sep 7:28 AM)